Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSarkar, Susobhan-
dc.contributor.authorGhosh, Anirban-
dc.contributor.authorDutta, Shukla-
dc.contributor.authorRoy, Ram Uday-
dc.contributor.authorBegum, Zarina-
dc.contributor.authorMukherjee, Joydeep-
dc.contributor.authorChaudhuri, Samares-
dc.contributor.authorChaudhuri, Swapna-
dc.identifier.issn0975-1009 (Online); 0019-5189 (Print)-
dc.description.abstractThe significant insights into the immunobiology of central nervous system (CNS) and brain tumor have opened up the feasibility of applying 'Immunotherapy' as an alternative to the poor prognosis of malignant brain tumor with conventional therapeutic approaches. Though cytokines like IL-2 and IFN-γ used against glioma showed some favorable results by eliciting Th1 type immune response, a proper immunotherapeutic agent is still to be searched for. Sheep erythrocyte (SRBC), a corpuscular antigen showed a better therapeutic efficacy in terms of enhanced survival and augmentation of cell mediated immunity (CMI) in a glioma model developed by chemical carcinogen ethyl nitrosourea. Histological tindings revealed most efficient glioma rejection in SRBC and combination biological response modifier (BRM) treated groups. Simultaneously E-rosetting, cytotoxicity of lymphocytes, phagocytosis and antigen presenting capacity of myeloid cells established the better therapeutic efficacy of SRBC alone than other BRMs viz. IL-2 and IFN-γ. Even the effect of combination therapy of different BRMs showed marginal differences in facilitating glioma reduction than the single use of SRBC. These findings emphasized the application of SRBC as an exogenous BRM having the potential as a rational therapeutic adjunct against glioma.en_US
dc.publisherNISCAIR-CSIR, Indiaen_US
dc.rights CC Attribution-Noncommercial-No Derivative Works 2.5 Indiaen_US
dc.sourceIJEB Vol.43(05) [May 2005]en_US
dc.titleSheep erythrocyte demonstrated better effect than IL-2 and IFN-γ as biological response modifier against glioma in experimental modelen_US
Appears in Collections:IJEB Vol.43(05) [May 2005]

Files in This Item:
File Description SizeFormat 
IJEB 43(5) 414-419.pdf1.49 MBAdobe PDFView/Open

Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.